Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.46 |
| ▸ | CA1 | P00915 | 11/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974177 | 0.93 | CA2 (0.48) | CA2CA1CA9MMP1MMP2 | |
| SCHEMBL777502 | 0.89 | CA1 (0.52) | CA2CA1CA9 | |
| SCHEMBL75966 | 0.85 | CA2 (0.45) | CA2CA1CA9MMP1MMP2 | |
| SCHEMBL1758440 | 0.85 | CA2 (0.45) | CA2CA1CA9MMP1MMP2 | |
| SCHEMBL972507 | 0.84 | CA1 (0.52) | CA2CA1CA9 | |
| SCHEMBL3027542 | 0.83 | CA2 (0.44) | CA2CA1CA9MMP1MMP2 | |
| SCHEMBL15827020 | 0.83 | CA2 (0.44) | CA2CA1CA9MMP1MMP2 | |
| SCHEMBL76110 | 0.80 | CA2 (0.42) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL31178999 | 0.79 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL22117318 | 0.79 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12431537-B2 | Electrolyte including electrolyte solvent, fluoroether, and bis(fluorosulfonyl) salt, and lithium metal electrochemical cells including the same | 24M TECHNOLOGIES, INC. (US) | 2025-09-30 | — | — | US | claimed |
| US-20250260060-A1 | HIGH PERFORMANCE ELECTROLYTE FOR ELECTROCHEMICAL ENERGY STORAGE DEVICES, AND METHODS OF PRODUCING THE SAME | 24M TECHNOLOGIES, INC. | 2025-08-14 | — | — | US | claimed |
| CN-120117732-A | Method for removing perfluoro and polyfluoroalkyl compounds | 北京大学深圳研究生院 | 2025-06-10 | — | — | CN | claimed |
| US-20240363910-A1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE CONTAINING SAME | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2024-10-31 | — | — | US | claimed |
| CN-118198493-A | Electrolyte for sodium ion battery suitable for hard carbon negative electrode and sodium ion battery | 天能电池集团股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2023130423-A1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE COMPRISING SAME | 宁德新能源科技有限公司 | 2023-07-13 | — | — | WO | claimed |
| CN-113871720-A | High-safety electrolyte and preparation method and application thereof | 厦门大学 | 2021-12-31 | — | — | CN | claimed |
| CN-112778838-A | Inorganic nano material printing ink and preparation method thereof | 广东绿展科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| US-10066152-B2 | Crosslinkable proppant particulates for use in subterranean formation operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2018-09-04 | — | — | US | claimed |
| US-20170198208-A1 | Crosslinkable Proppant Particulates For Use In Subterranean Formation Operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-13 | — | — | US | claimed |
| WO-2016025002-A1 | CROSSLINKABLE PROPPANT PARTICULATES FOR USE IN SUBTERRANEAN FORMATION OPERATIONS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| EP-2266159-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2013-10-23 | — | — | EP | claimed |
| US-8277972-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2012-10-02 | — | — | US | claimed |
| US-20110008684-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG ENERGY SOLUTION, LTD. (KR) | 2011-01-13 | — | — | US | claimed |
| EP-2266159-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG Chem, Ltd. (KR) | 2010-12-29 | — | — | EP | claimed |
| WO-2009116740-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2009-09-24 | — | — | WO | claimed |
| US-6599922-B2 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide (FLECAINIDE) | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.P.A. (IT) | 2003-07-29 | — | — | US | claimed |
| US-20030032835-A1 | Antiarrhythmia agents | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.P.A (IT) | 2003-02-13 | — | — | US | claimed |
| EP-1283201-A1 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidyl-methyl)-benzamide (flecanide) | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. (IT) | 2003-02-12 | — | — | EP | claimed |
| JP-2152955-A | — | — | None | — | — | JP | disclosed |
| EP-4355748-B1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20260005313-A1 | ELECTROLYTE INCLUDING ELECTROLYTE SOLVENT, FLUOROETHER, AND BIS(FLUOROSULFONYL) SALT, AND LITHIUM METAL ELECTROCHEMICAL CELLS INCLUDING THE SAME | 24M TECHNOLOGIES, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12476284-B2 | Non-aqueous electrolyte solution, cell pack, and method for manufacturing cell pack | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-11-18 | — | — | US | disclosed |
| US-20250309353-A1 | HIGH PERFORMANCE ELECTROLYTE FOR ELECTROCHEMICAL ENERGY STORAGE DEVICES, AND METHODS OF PRODUCING THE SAME | 24M TECHNOLOGIES, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250300231-A1 | HIGH PERFORMANCE ELECTROLYTE FOR ELECTROCHEMICAL ENERGY STORAGE DEVICES, AND METHODS OF PRODUCING THE SAME | 24M TECHNOLOGIES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| CN-120117732-A | Method for removing perfluoro and polyfluoroalkyl compounds | 北京大学深圳研究生院 | 2025-06-10 | — | — | CN | disclosed |
| US-20250110101-A1 | PER AND POLYFLUOROALKYL SUBSTANCE MEASUREMENT | DEXSIL CORPORATION (US) | 2025-04-03 | — | — | US | disclosed |
| US-12252423-B2 | Biodegradation of fluorochemicals | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240383901-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-11-21 | — | — | US | disclosed |
| US-20240363910-A1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE CONTAINING SAME | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2024-10-31 | — | — | US | disclosed |
| WO-2024203772-A1 | METHOD FOR PRODUCING ALPHA-CYANOACRYLATE | 東亞合成株式会社 | 2024-10-03 | — | — | WO | disclosed |
| CN-118198493-A | Electrolyte for sodium ion battery suitable for hard carbon negative electrode and sodium ion battery | 天能电池集团股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240190735-A1 | ENHANCING AMMONIUM OXIDATION AND FLUOROCHEMICAL DEGRADATION WITH FERRIC IRON PHASE COMPRISING POLYMERIC COATINGS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-06-13 | — | — | US | disclosed |
| EP-4355748-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-04-24 | — | — | EP | disclosed |
| US-20240059860-A1 | METHODS AND SYSTEMS FOR DESTRUCTION OF SYNTHETIC PER- AND POLYFLUORO COMPOUNDS | CHZ TECHNOLOGIES, LLC | 2024-02-22 | — | — | US | disclosed |
| US-20230264986-A1 | NANOCOMPOSITE SEPARATION MEDIA AND METHODS OF MAKING THE SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE | 2023-08-24 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230198096-A1 | ELECTROCHEMICAL DEVICE | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4157823-A1 | COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-04-05 | — | — | EP | disclosed |
| US-20230087560-A1 | HYDROFLUORETHERS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY | 2023-03-23 | — | — | US | disclosed |
| CN-115667225-A | Compound (I) | 詹森药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263472-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-12-22 | — | — | WO | disclosed |
| EP-4105218-A1 | SUBSTITUTED PYRROLO[2,3-D] PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-12-21 | — | — | EP | disclosed |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | Janssen Biopharma, Inc. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220320585-A1 | Non-Aqueous Electrolyte Solution, Cell Pack, and Method for Manufacturing Cell Pack | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2022-10-06 | — | — | US | disclosed |
| US-20220298126-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-22 | — | — | US | disclosed |
| CN-114981236-A | Hydrofluoroethers and methods of use thereof | 3M创新有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114716426-A | Antiviral compounds | 詹森生物制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4013744-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | disclosed |
| EP-3998664-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, CELL PACK, AND METHOD FOR MANUFACTURING CELL PACK | Asahi Kasei Kabushiki Kaisha (JP) | 2022-05-18 | — | — | EP | disclosed |
| CN-105636936-B | Antiviral compounds | 詹森生物制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114287077-A | Nonaqueous electrolyte solution, battery pack, and method for producing battery pack | 旭化成株式会社 | 2022-04-05 | — | — | CN | disclosed |
| CN-114269726-A | Process for preparing 2- (phenylimino) -3-alkyl-1, 3-thiazolidin-4-ones | 拜耳公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-113871720-A | High-safety electrolyte and preparation method and application thereof | 厦门大学 | 2021-12-31 | — | — | CN | disclosed |
| WO-2021241762-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, CELL PACK, AND METHOD FOR MANUFACTURING CELL PACK | 旭化成株式会社 | 2021-12-02 | — | — | WO | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| US-20210340042-A1 | BIODEGRADATION OF FLUOROCHEMICALS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2021-11-04 | — | — | US | disclosed |
| WO-2021144678-A1 | HYDROFLUORETHERS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-07-22 | — | — | WO | disclosed |
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| CN-112778838-A | Inorganic nano material printing ink and preparation method thereof | 广东绿展科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-108137502-B | Pyridine compound | 住友化学株式会社 | 2021-03-16 | — | — | CN | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3366674-B1 | PYRIDINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-107074779-B | Pyridazine compounds | 住友化学株式会社 | 2020-05-01 | — | — | CN | disclosed |
| WO-2020069347-A1 | BIODEGRADATION OF FLUOROCHEMICALS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-04-02 | — | — | WO | disclosed |
| CN-107074781-B | Pyrimidinone compounds | 住友化学株式会社 | 2020-01-17 | — | — | CN | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3202762-B1 | PYRIMIDINONE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-10273210-B2 | Pyridine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20180297953-A1 | PYRIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-10-18 | — | — | US | disclosed |
| US-10066152-B2 | Crosslinkable proppant particulates for use in subterranean formation operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| EP-3366674-A1 | PYRIDINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| EP-3319956-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-3131905-B1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-28 | — | — | EP | disclosed |
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9834559-B2 | 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-05 | — | — | US | disclosed |
| EP-2731188-B1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING SAME | LG CHEMICAL LTD (KR) | 2017-11-22 | — | — | EP | disclosed |
| US-9802930-B1 | Pyrimidinone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20170305896-A1 | PYRIMIDINONE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9738652-B2 | Spiro urea compounds as RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-22 | — | — | US | disclosed |
| EP-3202762-A1 | PYRIMIDINONE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2017-08-09 | — | — | EP | disclosed |
| EP-2094633-B1 | HYDROFLUOROETHER COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | 3M INNOVATIVE PROPERTIES CO (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170198208-A1 | Crosslinkable Proppant Particulates For Use In Subterranean Formation Operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-2909195-B1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2738860-B1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING SAME | LG CHEMICAL LTD (KR) | 2017-05-03 | — | — | EP | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| EP-3008067-B1 | 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO[1,5-A]PYRAZIN-3(2H)-ONE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-29 | — | — | EP | disclosed |
| EP-3131905-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2017-02-22 | — | — | EP | disclosed |
| US-20170044172-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-02-16 | — | — | US | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| WO-2017005725-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | WO | disclosed |
| EP-2027100-B1 | CYCLIC HYDROFLUOROETHER COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160115171-A1 | 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO[1,5-A]PYRAZIN-3(2H)-ONE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-28 | — | — | US | disclosed |
| EP-2850083-B1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | JANSSEN PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-3008067-A1 | 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO[1,5-A]PYRAZIN-3(2H)-ONE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | Janssen Pharmaceutica N.V. (BE) | 2016-04-20 | — | — | EP | disclosed |
| WO-2016025002-A1 | CROSSLINKABLE PROPPANT PARTICULATES FOR USE IN SUBTERRANEAN FORMATION OPERATIONS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| EP-2721104-B1 | RADIATION CURABLE POLY(ISOBUTYLENE) ADHESIVE COPOLYMERS HAVING PENDENT AMINE GROUPS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| WO-2015158653-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-22 | — | — | WO | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150259367-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-9054390-B2 | Electrolyte for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2015-06-09 | — | — | US | disclosed |
| US-9054390-B2 | Electrolyte for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2015-06-09 | — | — | US | disclosed |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | CELLZOME LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| EP-2850083-A1 | SUBSTITUTED 3, 4 - DIHYDRO - 2H - PYRIDO [1, 2 -A]PYRAZINE - 1, 6 - DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | Janssen Pharmaceuticals, Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| WO-2014198851-A1 | 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO[1,5-A]PYRAZIN-3(2H)-ONE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | WO | disclosed |
| US-8835482-B2 | Substituted indazole and aza-indazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8791254-B2 | Cyclic hydrofluoroether compounds and processes for their preparation and use | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-8758934-B2 | Electrolyte for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2014-06-24 | — | — | US | disclosed |
| US-8758934-B2 | Electrolyte for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2014-06-24 | — | — | US | disclosed |
| EP-2721104-A1 | RADIATION CURABLE POLY(ISOBUTYLENE) ADHESIVE COPOLYMERS HAVING PENDENT AMINE GROUPS | 3M Innovative Properties Company (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8673995-B2 | Radiation curable poly(isobutylene) adhesive copolymers having pendent amine groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2013171712-A1 | SUBSTITUTED 3, 4 - DIHYDRO - 2H - PYRIDO [1, 2 -A] PYRAZINE - 1, 6 - DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | Janssen Pharmaceuticals, Inc. (US) | 2013-11-21 | — | — | WO | disclosed |
| EP-2313365-B1 | AQUEOUS METHODS FOR MAKING FLUORINATED SULFONATE ESTERS | 3M INNOVATIVE PROPERTIES CO (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2266159-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2013-10-23 | — | — | EP | disclosed |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2427453-B1 | SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8486937-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130102699-A1 | Radiation Curable Poly(isobutylene) Adhesive Copolymers Having Pendent Amine Groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012177530-A1 | RADIATION CURABLE POLY(ISOBUTYLENE) ADHESIVE COPOLYMERS HAVING PENDENT AMINE GROUPS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120322910-A1 | RADIATION CURABLE POLY(ISOBUTYLENE) ADHESIVE COPOLYMERS HAVING PENDENT AMINE GROUPS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8277972-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2012-10-02 | — | — | US | disclosed |
| US-8263619-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-8236819-B2 | Dihydro-[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-07 | — | — | US | disclosed |
| US-8236819-B2 | Dihydro-[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-07 | — | — | US | disclosed |
| US-8193397-B2 | Comprising terminal (perfluoroalkyl) groups and intervening oxytetrafluoroethylidene moiety bonded through its central carbon atom to an alkoxy- or fluoroalkoxy-substituted fluoromethylene moiety, each of said terminal having at least one catenated heteroatom; ozone depletion potential, global warming | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120095036-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| EP-2427453-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | XIE WENGE (US) | 2011-12-29 | — | — | US | disclosed |
| EP-2336128-A1 | Benzoisothiazoles and preparation and uses thereof | Memory Pharmaceuticals Corporation (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2313365-A1 | AQUEOUS METHODS FOR MAKING FLUORINATED SULFONATE ESTERS | 3M Innovative Properties Company (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1907360-B1 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | GLADE ORGANICS PRIVATE LTD (IN) | 2011-03-30 | — | — | EP | disclosed |
| US-20110008684-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG ENERGY SOLUTION, LTD. (KR) | 2011-01-13 | — | — | US | disclosed |
| EP-2266159-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG Chem, Ltd. (KR) | 2010-12-29 | — | — | EP | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| WO-2010145883-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100184990-A1 | Process for the Manufacture of Flecainide | GLADE ORGANICS PRIVATE LIMITED (IN) | 2010-07-22 | — | — | US | disclosed |
| US-7759512-B2 | Aqueous methods for making fluorinated sulfonate esters | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-07-20 | — | — | US | disclosed |
| US-7723326-B2 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723326-B2 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
| US-20100105728-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | LAGU BHARAT | 2010-04-29 | — | — | US | disclosed |
| US-20100105728-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | LAGU BHARAT | 2010-04-29 | — | — | US | disclosed |
| WO-2010011454-A1 | AQUEOUS METHODS FOR MAKING FLUORINATED SULFONATE ESTERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100016624-A1 | AQUEOUS METHODS FOR MAKING FLUORINATED SULFONATE ESTERS | 3M INNOVATIVE PROPERTIES COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-7638533-B2 | 3-[3-(1-Ethyl-4,4,6-trimethyl-2-oxo- 1,2,3,4-tetrahydro-quinolin-7-yl)-4- (2,2,2-trifluoro-ethoxy)-phenyl]- acrylic acid;Retinoid X Receptor (RXR) agonists useful for treating the onset of cancer and metabolic disorders such as diabetes, dyslipidemia, and hypercholesterolemia | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7638533-B2 | 3-[3-(1-Ethyl-4,4,6-trimethyl-2-oxo- 1,2,3,4-tetrahydro-quinolin-7-yl)-4- (2,2,2-trifluoro-ethoxy)-phenyl]- acrylic acid;Retinoid X Receptor (RXR) agonists useful for treating the onset of cancer and metabolic disorders such as diabetes, dyslipidemia, and hypercholesterolemia | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| WO-2009116740-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2009-09-24 | — | — | WO | disclosed |
| EP-2094633-A1 | HYDROFLUOROETH R COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | 3M Innovative Properties Company (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1907360-A4 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | GLADE ORGANICS PRIVATE LTD (IN) | 2009-04-01 | — | — | EP | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| EP-2027100-A2 | CYCLIC HYDROFLUOROETHER COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | 3M Innovative Properties Company (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1948623-A2 | HETEROCYCLIC AMIDE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| EP-1937641-A2 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937657-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008070606-A1 | HYDROFLUOROETHΞR COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139683-A1 | HYDROFLUOROETHER COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | 3M INNOVATIVE PROPERTIES COMPANY | 2008-06-12 | — | — | US | disclosed |
| EP-1907360-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | Glade Organics Private Limited (IN) | 2008-04-09 | — | — | EP | disclosed |
| EP-1865956-A2 | PIPERIDINYL SUBSTITUTED CYCLOHEXANE-1,4-DIAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007136948-A2 | CYCLIC HYDROFLUOROETHER COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070267464-A1 | CYCLIC HYDROFLUOROETHER COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| EP-1807081-A1 | CYCLOHEXYLDIAMINES AS SELECTIVE ALPHA 1A/1D ADRENORECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041112-A2 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041077-A2 | HETEROCYCLIC AMIDE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. | 2007-04-05 | — | — | US | disclosed |
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. | 2007-04-05 | — | — | US | disclosed |
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-05 | — | — | US | disclosed |
| WO-2007003982-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | GLADE ORGANICS PRIVATE LIMITED (IN) | 2007-01-11 | — | — | WO | disclosed |
| EP-1735306-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006101859-A2 | PIPERIDINYL SUBSTITUTED CYCLOHEXANE-1,4-DIAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | US | disclosed |
| US-20060173015-A1 | Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-03 | — | — | US | disclosed |
| WO-2006050048-A1 | CYCLOHEXYLDIAMINES AS SELECTIVE ALPHA 1A/1D ADRENORECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
| EP-1644340-A1 | N-{'4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL]ALKYL}-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | disclosed |
| WO-2005092890-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |
| US-6599922-B2 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide (FLECAINIDE) | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.P.A. (IT) | 2003-07-29 | — | — | US | disclosed |
| US-6599922-B2 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide (FLECAINIDE) | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.P.A. (IT) | 2003-07-29 | — | — | US | disclosed |
| US-20030032835-A1 | Antiarrhythmia agents | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.P.A (IT) | 2003-02-13 | — | — | US | disclosed |
| US-20030032835-A1 | Antiarrhythmia agents | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.P.A (IT) | 2003-02-13 | — | — | US | disclosed |
| EP-1283201-A1 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidyl-methyl)-benzamide (flecanide) | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. (IT) | 2003-02-12 | — | — | EP | disclosed |
| EP-1283201-A1 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidyl-methyl)-benzamide (flecanide) | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. (IT) | 2003-02-12 | — | — | EP | disclosed |
| EP-0898556-B1 | A PROCESS FOR THE PRODUCTION OF HYDROFLUOROETHERS | MINNESOTA MINING & MFG (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1010696-A1 | Method of preparing Oxoquazepam | SSP Co., Ltd. (JP) | 2000-06-21 | — | — | EP | disclosed |
| EP-0898556-A1 | A PROCESS FOR THE PRODUCTION OF HYDROFLUOROETHERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5750797-A | CONTACTING A FLUORINATED CARBONYL-CONTAINING COMPOUND WITH AN ALKYLATING AGENT IN THE PRESENCE OF AN ANHYDROUS SOURCE OF FLUORIDE ION AND A TERTIARY AMINE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997038962-A1 | A PROCESS FOR THE PRODUCTION OF HYDROFLUOROETHERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| JP-H02152955-A | TRIFLUOROETHYL PERFLUOROBUTANESULFONATE | FAB IT SINTETICH SPA | 1990-06-12 | — | — | JP | disclosed |
| JP-H02152955-A | TRIFLUOROETHYL PERFLUOROBUTANESULFONATE | FAB IT SINTETICH SPA | 1990-06-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (38 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | CA2 2830/4885CA1 4057/4885CA9 4721/4885 |
| US-20240383901-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | LRRK2, PARK7, SNCA | CA2 4553/4885CA1 4853/4885CA9 4855/4885 |
| US-20260005313-A1 | ELECTROLYTE INCLUDING ELECTROLYTE SOLVENT, FLUOROETHER, AND BIS(FLUOROSULFONYL) SALT, AND LITHIUM METAL ELECTROCHEMICAL CELLS INCLUDING THE SAME | HCN1, TET1, KCNN1 | CA2 66/4885CA1 20/4885CA9 709/4885 |
| US-20070267464-A1 | CYCLIC HYDROFLUOROETHER COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | AFF4, CYP4F3, CYP2F1 | CA2 128/4885CA1 224/4885CA9 424/4885 |
| US-20170044172-A1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | REN, ZC3HAV1, SAV1 | CA2 4654/4885CA1 4846/4885CA9 3298/4885 |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CA2 3830/4885CA1 4791/4885CA9 3275/4885 |
| US-20060173015-A1 | Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | ADRA1D, ADRA1A, ADRB1 | CA2 2458/4885CA1 4138/4885CA9 3583/4885 |
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | ADRA1D, ADRA1A, ADRB1 | CA2 1804/4885CA1 3883/4885CA9 4019/4885 |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | PPARD, PPARG, PPARA | CA2 4379/4885CA1 4790/4885CA9 4755/4885 |
| US-20220298126-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | CYP1A1, CYP4B1, CYP1A2 | CA2 2716/4885CA1 4180/4885CA9 4736/4885 |
| US-20230087560-A1 | HYDROFLUORETHERS AND METHODS OF USING SAME | NPFFR2, CYP2F1, CYP4F3 | CA2 345/4885CA1 1218/4885CA9 1414/4885 |
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CA2 3871/4885CA1 3953/4885CA9 4351/4885 |
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | NR1H2, RXRA, NR1H3 | CA2 4247/4885CA1 4718/4885CA9 4461/4885 |
| US-10421742-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | CA2 1924/4885CA1 4853/4885CA9 3355/4885 |
| US-11180471-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | CA2 1924/4885CA1 4853/4885CA9 3355/4885 |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | CA2 1924/4885CA1 4853/4885CA9 3355/4885 |
| US-20120095036-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | CA2 3614/4885CA1 1950/4885CA9 4290/4885 |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CA2 3837/4885CA1 3999/4885CA9 4332/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | CA2 3830/4885CA1 4791/4885CA9 3275/4885 |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | CA2 64/4885CA1 1845/4885CA9 300/4885 |
| US-20170305896-A1 | PYRIMIDINONE COMPOUND | C5, C3AR1, CCR3 | CA2 1593/4885CA1 1909/4885CA9 2192/4885 |
| US-20080139683-A1 | HYDROFLUOROETHER COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE | OGFOD1, AQP3, FOS | CA2 1376/4885CA1 1112/4885CA9 1635/4885 |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CA2 3830/4885CA1 4791/4885CA9 3275/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CA2 3830/4885CA1 4791/4885CA9 3275/4885 |
| US-20180297953-A1 | PYRIDINE COMPOUND | PNPO, NOX4, CYP4X1 | CA2 2250/4885CA1 3558/4885CA9 2296/4885 |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | CA2 1924/4885CA1 4853/4885CA9 3355/4885 |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CA2 3830/4885CA1 4791/4885CA9 3275/4885 |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | CA2 3006/4885CA1 1012/4885CA9 4475/4885 |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | CA2 1924/4885CA1 4853/4885CA9 3355/4885 |
| US-20160115171-A1 | 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO[1,5-A]PYRAZIN-3(2H)-ONE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | CA2 3607/4885CA1 3817/4885CA9 4803/4885 |
| US-20100105728-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | NR1H2, RXRA, NR1H3 | CA2 4247/4885CA1 4718/4885CA9 4461/4885 |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | NR1H2, NR1H3, RXRA | CA2 4551/4885CA1 4731/4885CA9 4249/4885 |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | CA2 96/4885CA1 179/4885CA9 219/4885 |
| US-10273210-B2 | Pyridine compound | PNPO, NOX4, CYP4X1 | CA2 2250/4885CA1 3558/4885CA9 2296/4885 |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CA2 3871/4885CA1 3953/4885CA9 4351/4885 |
| US-20150259367-A1 | RSV ANTIVIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, RTF1 | CA2 3685/4885CA1 4818/4885CA9 3828/4885 |
| US-20100184990-A1 | Process for the Manufacture of Flecainide | KCND2, KCNH1, KCNH2 | CA2 18/4885CA1 202/4885CA9 142/4885 |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA3 | CA2 3837/4885CA1 3999/4885CA9 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.